Literature DB >> 9666145

Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration.

J J Pei1, I Grundke-Iqbal, K Iqbal, N Bogdanovic, B Winblad, R F Cowburn.   

Abstract

Cyclin-dependent kinase 5 (cdk5) is one of the candidate kinases involved in the abnormal hyperphosphorylation of tau. To have a direct effect on tau hyperphosphorylation, cdk5 protein levels and enzyme activity should be upregulated in especially those neurons that develop neurofibrillary tangles (NFTs). We studied the distribution of cdk5 immunoreactivity in neurons with or without early- and late-stage NFTs in hippocampal, entorhinal, transentorhinal, temporal and frontal cortices, and cerebellum of Alzheimer's disease (AD) and control brain. The immunocytochemical localisation of cdk5 was compared with that obtained using antibodies to PHF-tau (tau in paired helical filaments of NFTs, mAb AT8) and ubiquitin as markers of early and late stage NFTs, respectively. Immunoreactivities of cdk5 and PHF-tau were found in neuronal perikarya and processes of hippocampal, entorhinal, transentorhinal, temporal and frontal, and cerebellar cortices. An apparent increase of cdk5 immunoreactivity was seen in pretangle neurons and in neurons bearing early stage NFTs. These findings suggest that this kinase might be involved in the formation of NFTs at a relatively early stage in the neocortex. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9666145     DOI: 10.1016/s0006-8993(98)00296-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  60 in total

1.  [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].

Authors:  A Schneider; P Falkai; A Papassotiropoulos
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

Review 2.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

3.  Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.

Authors:  Masashi Kitazawa; Kim N Green; Antonella Caccamo; Frank M LaFerla
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

4.  Physiological regulation of tau phosphorylation during hibernation.

Authors:  Bo Su; Xinglong Wang; Kelly L Drew; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Neurochem       Date:  2008-06-01       Impact factor: 5.372

Review 5.  Tau in neurodegenerative disease.

Authors:  Yong-Lei Gao; Nan Wang; Fu-Rong Sun; Xi-Peng Cao; Wei Zhang; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2018-05

6.  Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model.

Authors:  Ahmet Turan Isik; Turgay Celik; Gokhan Ulusoy; Onder Ongoru; Birsen Elibol; Huseyin Doruk; Ergun Bozoglu; Hakan Kayir; Mehmet Refik Mas; Serif Akman
Journal:  Age (Dordr)       Date:  2008-10-08

Review 7.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

8.  Cdk5 regulates the organization of Nestin and its association with p35.

Authors:  Cecilia M Sahlgren; Andrey Mikhailov; Samuli Vaittinen; Hanna-Mari Pallari; Hannu Kalimo; Harish C Pant; John E Eriksson
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

9.  Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy.

Authors:  Elizabeth A Grace; Jorge Busciglio
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

10.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.